TP53 mutations and 17p13 deletions are independent prognostic factors for PFS in previously treated CLL patients (n = 446)
| Variable . | Comparison (no. of patients) . | HR (95%CI) . | P* . |
|---|---|---|---|
| RND | FC vs FCR | 0.61 (0.48-0.76) | <.001 |
| Binet stage | A/B vs C | 1.64 (1.29-2.09) | <.001 |
| Age | Continuous | 1.01 (1.00-1.02) | .090 |
| IGVH | Mutated vs unmutated | 2.40 (1.85-3.10) | <.001 |
| Del17p | No vs yes (37) | 1.72 (1.07-2.74) | .024 |
| TP53 | Wild type vs mutation (52) | 1.73 (1.14-2.61) | .009 |
| Variable . | Comparison (no. of patients) . | HR (95%CI) . | P* . |
|---|---|---|---|
| RND | FC vs FCR | 0.61 (0.48-0.76) | <.001 |
| Binet stage | A/B vs C | 1.64 (1.29-2.09) | <.001 |
| Age | Continuous | 1.01 (1.00-1.02) | .090 |
| IGVH | Mutated vs unmutated | 2.40 (1.85-3.10) | <.001 |
| Del17p | No vs yes (37) | 1.72 (1.07-2.74) | .024 |
| TP53 | Wild type vs mutation (52) | 1.73 (1.14-2.61) | .009 |
del17p, 17p13 deletion; CI, confidence interval; RND, randomization.
P values were calculated using the Wald test.